1. Name and Address of Reporting Person
   Zaks Tal Zvi
   (Last) (First) (Middle)
   200 TECHNOLOGY SQUARE
   CAMBRIDGE MA 02139

2. Issuer Name and Ticker or Trading Symbol
   Moderna, Inc. [ MRNA ]

3. Date of Earliest Transaction (Month/Day/Year)
   05/19/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   05/19/2020

5. Relationship of Reporting Person(s) to Issuer
   X Director
   10% Owner
   Officer (give title below)
   Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>05/19/2020</td>
<td></td>
<td>V</td>
<td>A</td>
<td>12,563</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>05/19/2020</td>
<td></td>
<td>V</td>
<td>A</td>
<td>112,481</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>05/19/2020</td>
<td></td>
<td>S</td>
<td>D</td>
<td>125,044</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$12.21</td>
<td>05/19/2020</td>
<td></td>
<td>V</td>
<td>12,563</td>
<td>(2) 02/23/2027</td>
<td>Common Stock</td>
<td>12,563</td>
<td>$0</td>
<td>45,879</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$12.21</td>
<td>05/19/2020</td>
<td></td>
<td>V</td>
<td>112,481</td>
<td>(3) 03/03/2027</td>
<td>Common Stock</td>
<td>112,481</td>
<td>$0</td>
<td>346,234</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. This sale was effected pursuant to a Rule 10b5-1 trading plan.
2. 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
3. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

/s/ Lori Henderson, as Attorney-in-Fact
05/20/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

1. This form is filed by more than one reporting person, see Instruction 4 (b)(v).
3. Note: File three copies of this Form. one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.